H.C. Wainwright Keeps Their Buy Rating on CervoMed (CRVO)
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on CervoMed (CRVO) with a $25 price target. This follows Roth MKM's June 12 report, which also maintained a Buy rating but set a lower $9 target. Selvaraju, covering the healthcare sector, has a strong track record with a 22.4% average return and 58.8% success rate on recommendations.
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on CervoMed today and set a price target of $25.00.
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Selvaraju covers the Healthcare sector, focusing on stocks such as Cognition Therapeutics, Emergent Biosolutions, and Urogen Pharma. According to TipRanks, Selvaraju has an average return of 22.4% and a 58.80% success rate on recommended stocks.
In a report released on June 12, Roth MKM also reiterated a Buy rating on the stock with a $9.00 price target.